Hydrocortisone for the Treatment of Acute Respiratory Distress Syndrom: A Systematic Review and Meta-Analysis

Dea Selvia; Gede  Ardi Saputra

doi:10.58344/ihj.v5i3.945

Authors

Dea Selvia RS AKA Medika
Gede Ardi Saputra RSUP Prof dr IGNG Ngoerah

DOI:

https://doi.org/10.58344/ihj.v5i3.945

Keywords:

ARDS, Hydrocortison, Corticosteroid, Mortality, Meta-analysis

Abstract

Acute respiratory distress syndrome (ARDS) remains associated with substantial morbidity and mortality, while the efficacy and safety of hydrocortisone in its treatment remain uncertain. This study aimed to evaluate the efficacy and safety of hydrocortisone in patients with ARDS through a systematic review and meta-analysis of randomized controlled trials (RCTs). PubMed, the Cochrane Library, and the China National Knowledge Infrastructure (CNKI) database were searched for eligible studies published during the 20-year period preceding June 1, 2024. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the methodological quality of the included studies was assessed using the Cochrane risk-of-bias tool. Statistical analyses were performed using Review Manager (RevMan) version 5.3, with treatment effects expressed as odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Four RCTs involving 566 participants were included in the meta-analysis. Hydrocortisone treatment was associated with significantly lower overall mortality (OR = 0.60; 95% CI: 0.42–0.87). However, the reduction in 28-day mortality was not statistically significant (OR = 0.70; 95% CI: 0.45–1.08). No statistically significant differences were observed between treatment groups in the incidence of nosocomial infections or gastrointestinal bleeding. These findings suggested a potential survival benefit associated with hydrocortisone treatment in patients with ARDS. Nevertheless, variations in follow-up duration, clinical heterogeneity, and the limited number of included trials and participants restricted the strength and generalizability of the evidence. Hydrocortisone may have a beneficial role as an adjunctive treatment for ARDS; however, the available findings did not demonstrate a consistent improvement in short-term survival or establish definitive safety. Larger, adequately powered multicenter RCTs using standardized treatment regimens, consistent outcome definitions, and comprehensive adverse-event monitoring are warranted to clarify the efficacy and safety of hydrocortisone in ARDS management.

References

Annane, D., Sébille, V., Bellissant, E., & Ger-Inf-05 Study Group. (2006). Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Critical Care Medicine, 34(1), 22–30. https://doi.org/10.1097/01.ccm.0000194723.78632.62

Bellani, G., Laffey, J. G., Pham, T., Fan, E., Brochard, L., Esteban, A., et al. (2016). Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA, 315(8), 788–800. https://doi.org/10.1001/jama.2016.0291

Chang, X., Li, S., Fu, Y., Dang, H., & Liu, C. (2022). Safety and efficacy of corticosteroids in ARDS patients: a systematic review and meta-analysis of RCT data. Respiratory Research, 23(1), 301.

Chaudhuri, D., Nei, A. M., Rochwerg, B., Balk, R. A., Asehnoune, K., Cadena, R., et al. (2024). 2024 focused update: Guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Critical Care Medicine, 52(5), e219–e233. https://doi.org/10.1097/CCM.0000000000006172

Chaudhuri, D., Sasaki, K., Karkar, A., Sharif, S., Lewis, K., Mammen, M. J., Alexander, P., Ye, Z., Lozano, L. E. C., Munch, M. W., et al. (2021). Corticosteroids in COVID-19 and non-COVID-19 ARDS: A systematic review and meta-analysis. Intensive Care Medicine, 47(5), 521–537. https://doi.org/10.1007/s00134-021-06394-2

Confalonieri, M., Urbino, R., Potena, A., et al. (2005). Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. American Journal of Respiratory and Critical Care Medicine, 171(3), 242–248.

Dequin, P. F., Heming, N., Meziani, F., Plantefève, G., Voiriot, G., Badié, J., et al. (2020). Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomized clinical trial. JAMA, 324(13), 1298–1306. https://doi.org/10.1001/jama.2020.16761

European Medicines Agency. (2025). Guideline on the clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome (EMA/58320/2025 Rev. 2). European Medicines Agency.

Fan, E., Brodie, D., & Slutsky, A. S. (2018). Acute respiratory distress syndrome: Advances in diagnosis and treatment. JAMA, 319(7), 698–710.

Grasselli, G., Calfee, C. S., Camporota, L., Poole, D., Amato, M. B. P., Antonelli, M., Arabi, Y. M., Baroncelli, F., Beitler, J. R., Bellani, G., et al. (2023). ESICM guidelines on acute respiratory distress syndrome: Definition, phenotyping and respiratory support strategies. Intensive Care Medicine, 49(7), 727–759. https://doi.org/10.1007/s00134-023-07050-7

Ichikado, K., Kotani, T., Kondoh, Y., Imanaka, H., Johkoh, T., Fujimoto, K., Nunomiya, S., Kawayama, T., Sawada, M., & Jenkins, E. (2023). Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy–controlled, phase 2 multicenter study (ONE-BRIDGE). Stem Cell Research & Therapy, 14(1), 217.

Kuperminc, E., Heming, N., Carlos, M., & Annane, D. (2023). Corticosteroids in ARDS. Journal of Clinical Medicine, 12(9), Article 3340. https://doi.org/10.3390/jcm12093340

Kurahashi, K. (2022). Epidemiology and risk factors of ARDS: How many is the real incidence of ARDS? In S. Tasaka (Ed.), Acute respiratory distress syndrome (Respiratory Disease Series: Diagnostic Tools and Disease Managements). Springer. https://doi.org/10.1007/978-981-16-8371-8_2

Li, G., Chen, D., Gao, F., Huang, W., Wang, J., Li, Y., Chen, B., Zhong, Y., Chen, R., & Huang, M. (2024). Efficacy of corticosteroids in patients with acute respiratory distress syndrome: A meta-analysis. Annals of Medicine, 56(1). https://doi.org/10.1080/07853890.2024.2381086

Matthay, M. A., Arabi, Y., Arroliga, A. C., Bernard, G., Bersten, A. D., Brochard, L. J., Calfee, C. S., Combes, A., Daniel, B. M., Ferguson, N. D., Gong, M. N., Gotts, J. E., Herridge, M. S., Laffey, J. G., Liu, K. D., Machado, F. R., Martin, T. R., McAuley, D. F., Mercat, A., . . . Wick, K. D. (2024). A new global definition of acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine, 209(1), 37–47. https://doi.org/10.1164/rccm.202303-0558WS

Meyer, N. J., Gattinoni, L., & Calfee, C. S. (2021). Acute respiratory distress syndrome. The Lancet, 398(10300), 622–637.

Papazian, L., Aubron, C., Brochard, L., et al. (2019). Formal guidelines: Management of acute respiratory distress syndrome. Annals of Intensive Care, 9(1), Article 69. https://doi.org/10.1186/s13613-019-0540-9

Qadir, N., Sahetya, S., Munshi, L., Summers, C., Abrams, D., Beitler, J., Bellani, G., Brower, R. G., Burry, L., Chen, J.-T., et al. (2024). An update on management of adult patients with acute respiratory distress syndrome: An official American Thoracic Society clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 209(1), 24–36. https://doi.org/10.1164/rccm.202311-2011ST

Qadir, N., Sahetya, S., Munshi, L., Summers, C., Abrams, D., Beitler, J., Bellani, G., Brower, R. G., Burry, L., & Chen, J.-T. (2024). An update on management of adult patients with acute respiratory distress syndrome: an official American Thoracic Society clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 209(1), 24–36.

Ranieri, V. M., Rubenfeld, G. D., et al. (2012). Acute respiratory distress syndrome: The Berlin definition. JAMA, 307(23), 2526–2533.

Tongyoo, S., Permpikul, C., Mongkolpun, W., Vattanavanit, V., Udompanturak, S., Kocak, M., et al. (2016). Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: Results of a randomized controlled trial. Critical Care, 20(1), Article 329. https://doi.org/10.1186/s13054-016-1511-2

Wu, D., Li, Y., Dong, S.-H., & Gao, Y. (2024). Clinical outcomes of corticosteroid administration for acute respiratory distress syndrome in adults based on meta-analyses and trial sequential analysis. Annals of Saudi Medicine, 44(3), 167–182. https://doi.org/10.5144/0256-4947.2024.167